



# Hi-Affi™ Rabbit Anti-Human KRASG12V/HLA-A\*03:01 Complex Monoclonal antibody, clone V2 (DMAB-CDB26097)

This product is for research use only and is not intended for diagnostic use.

## PRODUCT INFORMATION

|                           |  |
|---------------------------|--|
| <b>Product Overview</b>   | V2 is a TCRm antibody against KRASG12V7–16-HLA-A*03:01. The hydrophobic interactions and an induced conformational change dictate V2 specificity for the KRASG12V peptide.   |
| <b>Specificity</b>        | V2 binds to the KRASG12V peptide presented by HLA-A*03:01.   |
| <b>Target</b>             | Human KRASG12V/HLA-A*03:01 Complex   |
| <b>Immunogen</b>          | Human KRASG12V/HLA-A*03:01 Complex   |
| <b>Isotype</b>            | IgG  |
| <b>Source/Host</b>        | Rabbit   |
| <b>Species Reactivity</b> | Human  |
| <b>Clone</b>              | V2   |
| <b>Purification</b>       | >90% determined by SDS-PAGE  |
| <b>Conjugate</b>          | Unconjugated   |
| <b>Applications</b>       | Suitable for use in SPR, Crystallography, EM.<br>Each laboratory should determine an optimum working titer for use in its particular application. Other applications have not been tested but use in such assays should not necessarily be excluded. |
| <b>Format</b>             | Liquid   |
| <b>Concentration</b>      | lot specific   |

|                     |  |
|---------------------|--|
| <b>Size</b>         | 200 µg, 1 mg   |
| <b>Buffer</b>       | PBS (endotoxin < 1EU/mg, lower endotoxin levels may also be offered upon request)      |
| <b>Preservative</b> | None   |
| <b>Storage</b>      | Short term at 2-8°C; long term storage in aliquots at -20°C; avoid freeze/thaw cycles. |
| <b>Ship</b>         | Dry ice  |

## BACKGROUND

|                     |   |
|---------------------|---|
| <b>Introduction</b> | Monoclonal antibodies are at the vanguard of the most promising cancer treatments. Whereas traditional therapeutic antibodies have been limited to extracellular antigens, T cell receptor mimic (TCRm) antibodies can target intracellular antigens presented by cell surface major histocompatibility complex (MHC) proteins. TCRm antibodies can therefore target a repertoire of otherwise undruggable cancer antigens. |
| <b>Keywords</b>     | KRAS; HLA-A; HLA-A3; HLA-A*03:01; HLA-A Complex   |